Advertisement


James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma

2016 ASCO Annual Meeting

Advertisement

James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).



Related Videos

Gynecologic Cancers

Helen MacKay, MD, and Ursula A. Matulonis, MD, on Epithelial Ovarian Cancer: Results From the OV21-PETROC Trial

Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, and Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discuss findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.

Global Cancer Care

Eduardo L. Cazap, MD, PhD, and Mary Gospodarowicz, MD, on The South American Perspective of Cancer Research

Eduardo L. Cazap, MD, PhD, of the Latinamerican & Caribbean Society of Medical Oncology, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.

Multiple Myeloma

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial (Italian Language Version)

Antonio Palumbo, MD, of the University of Torino, discusses in Italian this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4). 

 To see the English language version of this video, please click here.

Neuroendocrine Tumors

Heinz-Josef Lenz, MD, and Jonathan R. Strosberg, MD, on the NETTER-1 Trial for Midgut Neuroendocrine Tumors

Heinz-Josef Lenz, MD, of the University of Southern California, and Jonathan R. Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discuss efficacy and safety results in patients with midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 4005).

Advertisement

Advertisement




Advertisement